Guard Therapeutics International AB (GUARD) AI Stock Analysis

• Market Cap: €465.87M
• Dividend Yield: N/A
• Average Volume (3M): 30.52K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.20
• Revenue Growth: N/A
• EPS Growth: -14.36%
• Country: SE
• Employees: 12
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 20,167,631
• 10 Day Avg. Volume: 24,875
• 30 Day Avg. Volume: 30,523
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

Guard Therapeutics International AB faces challenges typical of early-stage biotechnology companies, such as zero revenue and significant R&D expenses leading to ongoing losses. Despite a strong equity position with no debt, the financial health is concerning if the company fails to commercialize its research outcomes. The technical indicators suggest the stock is oversold, which may offer short-term trading opportunities. However, the negative P/E ratio and lack of dividends highlight valuation concerns typical for firms in this stage.

Guard Therapeutics International AB Business Overview & Revenue Model

Company Description

Guard Therapeutics International AB (GUARD) is a biopharmaceutical company focused on developing innovative therapies to protect and restore organ function in patients with acute kidney injury (AKI) and other conditions. The company is headquartered in Sweden and operates primarily in the biotechnology and medical research sectors. Its core product is ROSgard, a drug candidate designed to reduce tissue damage and preserve organ function.

How the Company Makes Money

Guard Therapeutics primarily makes money through the development and potential commercialization of its drug candidate, ROSgard. Revenue streams include potential milestone payments, royalties, and licensing agreements with pharmaceutical companies upon successful regulatory approval and commercialization. The company may also receive funding through research grants, partnerships, and collaborations with other biotech firms or research institutions. Significant factors contributing to its earnings include the successful advancement of ROSgard through clinical trials and securing strategic partnerships for distribution and marketing.

Guard Therapeutics International AB Financial Statement Overview

Summary

Guard Therapeutics International AB is in a typical early-stage biotechnology phase, marked by zero revenue, substantial R&D investments, and reliance on external financing to sustain operations. While the company has no debt and a strong cash position, the continuous net losses and negative cash flows pose risks if they persist without revenue growth.

Income Statement

Guard Therapeutics International AB has consistently reported zero revenue over the years, reflecting the early-stage nature typical of biotechnology firms. The company is experiencing significant net losses, which have gradually increased over time, indicating ongoing investment in research and development without corresponding revenue generation. Both EBIT and EBITDA margins are negative, further highlighting operational losses.

Balance Sheet

The company maintains a strong equity position with no debt, which is a positive aspect for financial stability. However, the equity has been declining over the years due to continued losses. The absence of revenue generation poses a risk to maintaining this balance in the long term, despite the current lack of leverage.

Cash Flow

Guard Therapeutics shows negative operating cash flow, consistent with its early-stage biotech status. While free cash flow is negative, there have been significant financing inflows, especially in the earlier years, which have helped sustain operations. However, the trend of increasing cash burn is concerning if not matched by future revenue generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-15.00K	-15.00K	-15.00K	-161.00K
EBITDA	-100.23M	-114.91M	-112.82M	-82.01M	-40.12M
Net Income	-96.07M	-113.32M	-110.76M	-82.16M	-40.29M
Balance Sheet
Total Assets	55.74M	85.23M	202.60M	190.44M	91.22M
Cash, Cash Equivalents and Short-Term Investments	54.19M	83.74M	201.01M	188.60M	90.04M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	17.77M	18.49M	25.24M	14.66M	11.54M
Stockholders Equity	37.97M	66.73M	177.36M	175.78M	79.69M
Cash Flow
Free Cash Flow	-94.75M	-116.05M	-102.14M	-77.59M	-37.96M
Operating Cash Flow	-94.75M	-116.05M	-102.14M	-77.59M	-37.96M
Investing Cash Flow	0.00	0.00	-1.00K	0.00	118.00K
Financing Cash Flow	62.66M	-779.00K	112.60M	176.30M	74.05M

Guard Therapeutics International AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GUARD, the sentiment is Positive. The current price of 22.5 is above the 20-day moving average (MA) of 21.74, above the 50-day MA of 19.53, and above the 200-day MA of 18.77, indicating a bullish trend. The MACD of 1.10 indicates Positive momentum. The RSI at 57.87 is Neutral, neither overbought nor oversold. The STOCH value of 42.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GUARD.

Guard Therapeutics International AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XBRANE	58 Neutral	€436.98M	―	-47.73%	―	45.52%	93.35%
ONCO	54 Neutral	kr1.13B	―		―	1.72%	32.54%
Sector *	51 Neutral	kr6.06B	7.76	-27.68%	2.23%	51.29%	15.89%
IVACC	48 Neutral	€332.29M	―	-24.61%	―	56.48%	40.18%
IMMU	47 Neutral	€397.93M	―	-16.60%	―	―	21.85%
GUARD	32 Underperform	€465.87M	―	-205.65%	―	―	-14.36%
CANTA	31 Underperform	€718.49M	―	-167.55%	―	―	37.89%